Reimagining Diabetes: From Molecular Mechanisms to Transformative Therapies (S2)
January 1-5, 2027
| Location to be Determined
Anna Krook, Jennifer Green and David Moller
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Saturday, January 2, 2027
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Daniel J. Drucker †, Lunenfeld-Tanenbaum Research Institute
Novel Disease Spaces in Metabolic Disease, Breadth and Impact of GLP1 based Medicines (Including CV-Renal, Alzheimer’s and Neurodegenerative Disorders) |
|
| 9:00–11:15 AM |
Fine Tuning our Understanding of Genetic Causes for Metabolic Disease |
|
| |
Ruth J Loos †, University of Copenhagen
Identification of Genes and Genetic Loci Contributing to the Risk of Obesity and Related Traits |
|
| |
Melina Claussnitzer †, Broad Institute, Harvard Medical School and Massachusetts General Hospital
Moving from Variant to Function |
|
| |
Bart O. Roep †, Leiden University Medical Center
New Genetic Signal Modulating T1 Diabetes Risk |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–12:15 PM |
Panel Discussion 1: Lessons from Diabetes-Obesity Clinical Trials |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 12:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
New Mechanisms with Clinical Results |
|
| |
David Moller, Third Rock Ventures
Overview of Emerging Clinical Trial Results - Impact and Implications |
|
| |
David Kendall †, Zealand Pharma
Amylin Biology-Rationale and Clinical Results |
|
| |
Scott Harris †, Altimmune Inc.
Harnessing Glucagon Agonism to Amplify Efficacy |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Breakthrough Opportunities for Type 1 Diabetes and Preservation of Pancreatic B-Cell Mass-Function |
|
| |
Matthias Hebrok †, University of California, San Francisco
Advances toward Realizing the Goal of Stem Cell-Derived Islet Replacement Therapies |
|
| |
Pedro Herrera †, University of Geneva
Regenerative Medicine, Islet Health, and Disease-Modifying Approaches |
|
| |
Kevan C. Herold †, Yale University
Clinical Trial Advances to Decode Beta Cell Resilience in Type 1 Diabetes: Cellular Pathways that Prevent Immune Destruction |
|
| |
Diane Mathis †, Harvard Medical School
Novel Therapies for Immunoprotection |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Disease Biology and Novel Therapeutic Targets |
|
| |
Anna Krook, Karolinska Institutet
Skeletal Muscle as a Player in Pathobiology and a Therapeutic Target Organ |
|
| |
Mitchell A. Lazar †, Perelman School of Medicine, University of Pennsylvania
Role of Adipose Tissue and Transcriptional Control of Metabolism |
|
| |
Alexander Pfeifer †, University of Bonn
Novel Therapeutic Approach to Augment Thermogenic Adipose Tissue |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Addressing Shortcomings and Expanding Use of Incretin-Based Therapies |
|
| |
Philip Larsen †, Sixpeaks Bio AG
Residual Challenges: Weight Regain, Sarcopenia, Long-Term Weight Maintenance |
|
| |
Rotonya Carr †, University of Washington
Treating Metabolic Dysfunction-Associated Steatotic Liver Disease |
|
| |
Brian Finan †, Eli Lilly
Incretin based Tri Agonists |
|
| |
Lotte Bjerre Knudsen †, Novo Nordisk A/S
Incretin-based Therapeutics for the Treatment of Neurodegenerative Diseases |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
New Approaches Aimed at Modulating Energy Balance |
|
| |
Randy J. Seeley †, University of Michigan
Neural Pathways Regulating Food Intake and Energy Balance |
|
| |
Katrin J. Svensson †, Stanford University
Novel Peptides (for Example: BRINP2-Related Peptide (BRP)) that Regulate Feeding and Obesity |
|
| |
Eleftheria Maratos-Flier †, Harvard Medical School and Alnylam
FGF21: What have we Learned from Mice and Human Trials? |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–10:00 AM |
Clinical Technology Innovations & Devices |
|
| |
Eric Topol †, The Scripps Research Institute
Approaches to Aging and Metabolic Disease Management |
|
| |
Emmanuel Opara †, Wake Forest Institute for Regenerative Medicine
The Bioartificial Pancreas |
|
| |
John Buse †, University of North Carolina School of Medicine
Glucose Sensing Insulin |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 10:00–11:00 AM |
Panel Discussion: What Does the Future Hold for Strategies to Predict, Prevent, and Treat Diabetes Mellitus |
|
| |
* Jennifer Green, Duke University
|
|
| 11:00–11:15 AM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
Wednesday, January 6, 2027
